The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Here are the details: An effective treatment, until it isn't: The UW–Madison team sought to understand why some patients with certain non-Hodgkin's lymphomas that originate in white blood cells ...

Non-Hodgkin lymphomas can be classified according to the speed at which they progress. Those that grow and spread slowly are described as ‘indolent’, one of the most common types of which is ...

T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...

Doctors group B-cell lymphomas based on: How the cancer cells look under a microscope Whether the cancer cells have certain proteins on their surface What kinds of gene changes are inside the ...

"The dosing of our first patient with IM-1021 advances that mission, as we work to establish safety and explore efficacy of ...

Each year, about 100,000 patients worldwide are affected by T-cell leukemias and lymphomas. Adults with relapsed T-cell cancers have limited therapeutic options and five-year survival rates of 7 ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

The ongoing Phase 1 trial (ClinicalTrials.gov Identifier: NCT06699771) will enroll up to approximately 48 patients diagnosed with relapsed or refractory NK and T‑cell malignancies. The primary ...

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...

Corvus Pharmaceuticals' Soquelitinib shows promise for PTCL & more, but financial risks and competition raise concerns. Learn more about CRVS stock here.